NYSE · Healthcare · Medical Devices
Abbott Laboratories (ABT)
As of Sep 25, 4:04 PM ET, Abbott Laboratories (ABT) last traded at $101.29, up 0.22% on the day. Its TickerHum research score is 48/100 (average). It reported revenue of $45.13B for the twelve months ending 2026-03-31, up 6.6% year over year, with a 17.1% operating margin.
Ratings
- Valuation: 70/100 — Strongest input: price / sales (ttm) 3.9x. Weakest: free-cash-flow yield 4.2 %.
- Growth: 21/100 — Strongest input: revenue growth (ttm, yoy) +6.6 %. Weakest: diluted eps growth (ttm, yoy) -53.6 %.
- Profitability: 56/100 — Strongest input: operating margin 17.1 %. Weakest: return on equity 12.1 %.
- Financial health: 42/100 — Strongest input: long-term debt / equity 0.57. Weakest: cash / long-term debt 0.23.
- Momentum: 39/100 — Strongest input: 3-month return +7.6 %. Weakest: 1-year return -24.2 %.
- Attention: 56/100 — Strongest input: headlines in the last 7 days 33. Weakest: volume vs 3-month average 0.8x.
- Risk: 61/100 — Strongest input: annualised volatility (1y) 26.9 %. Weakest: max drawdown (1y) -38.7 %.
- Data confidence: 83/100 — Strongest input: inputs available 95 %. Weakest: quote age (hours) 45 h.
Reported fundamentals
| Metric | Value | Period |
|---|---|---|
| Revenue | $45.13B | TTM ending 2026-03-31 · 10-Q |
| Revenue growth | 6.6% | TTM ending 2026-03-31 · 10-Q |
| Net income | $6.28B | TTM ending 2026-03-31 · 10-Q |
| Diluted EPS | $3.57 | TTM ending 2026-03-31 · 10-Q |
| Operating margin | 17.1% | TTM ending 2026-03-31 · 10-Q |
| Net margin | 13.9% | TTM ending 2026-03-31 · 10-Q |
| Free cash flow | $7.38B | TTM ending 2026-03-31 · 10-Q |
| Cash | $6.8B | as of 2026-03-31 · 10-Q |
| Long-term debt | $29.64B | as of 2026-03-31 · 10-Q |
| Debt / equity | 0.57 | as of 2026-03-31 · 10-Q |
Source: SEC EDGAR XBRL company facts (CIK 0000001800).
Prices: Yahoo Finance (public) — Free public Yahoo Finance data. Prices may be delayed and are for information only.